Knopp Biosciences: Knopp Biosciences LLC: Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
Dexpramipexole also significantly reduced nasal eosinophil peroxidase, a marker of airway eosinophilia Knopp Biosciences LLC today reported further clinical and biomarker data demonstrating that r...
Read full article »
Knopp Biosciences is a drug discovery company that develops and commercializes medicines for the treatment of immunological and neurological diseases.
Read more